Form 4: Nautilus Biotechnology Director Acquires 45,000 Stock Options

Director Vijay Satyanand Pande acquired 45,000 stock options in Nautilus Biotechnology, Inc. on June 14, 2024.

Summary

• On June 14, 2024, Vijay Satyanand Pande, a director of Nautilus Biotechnology, Inc., acquired 45,000 stock options.
• The exercise price of these options is $2.56.
• The options vest monthly over a year, contingent upon continuous service as a 'Service Provider' as defined in the Issuer's 2021 Equity Incentive Plan.
• The options expire on June 14, 2034.
• Following the transaction, Pande directly owns 45,000 derivative securities.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard disclosure of stock option acquisition. The director's confidence in the company is a slightly positive indicator.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are standard disclosures required by the SEC to ensure transparency in insider trading activities, providing investors with insights into the actions of company insiders.

Stakeholder Impact

• The acquisition of stock options by a director may have a slightly positive impact on shareholders, as it can signal confidence in the company's future prospects.

Key Dates